Emerging studies on retatrutides, a dual agonist for incretin hormone and gastric inhibitory polypeptide, indicate promising findings in treating weight gain and type 2 diabetes. Preliminary information from clinical trials show considerable reductions in body mass and bettered glucose regulation. Additional research is centered on long-term har… Read More